BIO-key International ( (BKYI) ) has released a notification of late filing.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
BIO-key International, Inc. has filed a Form 12b-25 to notify investors of a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The company is late on this quarterly SEC filing, which covers its most recent operating results and financial position.
The company cites challenges in compiling, presenting, and reviewing certain financial information as the main reason for the delay. Management states that completing the financial statements on time would have required unreasonable effort and expense, suggesting internal workload or process constraints rather than external shocks.
BIO-key expects to file the Form 10-Q (Quarter Report) as soon as reasonably practicable and no later than the fifth calendar day after the original due date. This indicates the delay should be short, but investors will have to wait a few more days for the full set of financials and accompanying disclosures.
The company is signaling notable operational improvement versus the same quarter last year based on preliminary figures. Revenue is expected to rise to about $2.15 million from $1.61 million, gross profit to about $1.77 million from $1.33 million, and basic and diluted loss per share to narrow sharply to $(0.15) from $(1.57).
Management cautions that these numbers are preliminary and may change once the reporting process is completed, underscoring the forward-looking nature of the estimates. Investors should treat the figures as indicative rather than final until the official Form 10-Q (Quarter Report) is filed with the SEC.
The filing also discloses that not all other required periodic reports over the last 12 months have been filed, which may concern regulatory-focused investors. Nonetheless, BIO-key states it is working through the remaining steps to complete the quarter’s report and maintain ongoing compliance with SEC reporting obligations.
The notification is signed on behalf of the company by Chief Financial Officer Cecilia Welch on May 18, 2026. Her signature reflects executive-level accountability for both the delay and the plan to bring the company’s reporting current in the very near term.
The most recent analyst rating on (BKYI) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.
Spark’s Take on BKYI Stock
According to Spark, TipRanks’ AI Analyst, BKYI is a Neutral.
The score is held down primarily by weak financial performance (persistent losses and cash burn) and a bearish technical trend (price below all key moving averages with negative MACD). Negative corporate events (Nasdaq delisting/OTC shift and filing delays) add meaningful risk. Partially offsetting these are improved balance-sheet optics and a more optimistic earnings outlook for 2026, but the turnaround still requires successful execution.
To see Spark’s full report on BKYI stock, click here.
More about BIO-key International
Average Trading Volume: 40,974
Technical Sentiment Signal: Sell
Current Market Cap: $4.61M
Find detailed analytics on BKYI stock on TipRanks’ Stock Analysis page.